My watch list  

Noradrenergic and specific serotonergic antidepressant

Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants.[1] They are thought to work by blocking presynaptic alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin. This results in increases in both noradrenergic and specific serotonergic transmission.

Examples of NaSSAs include:

  • Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®, Axit®)

NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.[2]

See also

  • Clinical depression


  1. ^ Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet 355 (9207): 911-8. PMID 10752718.
  2. ^ Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord 51 (3): 267-85. PMID 10333982. link

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Noradrenergic_and_specific_serotonergic_antidepressant". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE